Skip to main content

Advertisement

SpringerLink
Log in

Daily nasal spray of hPTH(1–34) for 3 months increases bone mass in osteoporotic subjects: a pilot study

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Introduction

Although intermittent parathyroid hormone (PTH) injection can lead to strong anabolic effects on bone, daily subcutaneous injection is a disadvantage for patient acceptance. We have developed a nasal spray formula of parathyroid peptide [hPTH(1–34)] with peak serum hPTH(1–34) concentrations by nasal spray of 1,000 μg similar to those by subcutaneous injections of 20 μg hPTH(1–34).

Methods

To determine the clinical efficacy and safety of nasal hPTH(1–34) spray, a randomized, open-labeled clinical trial was conducted in subjects with osteoporosis. Ninety osteoporotic subjects age 52–84 years (mean 66.5 years) were randomly assigned to receive either 250 μg (PTH250, n=31), 500 μg (PTH500, n=30), or 1,000 μg (PTH1000, n=29) of daily nasal hPTH(1–34) spray for 3 months. All received daily supplements of 300 mg calcium and 200 IU vitamin D3.

Results

Daily nasal hPTH(1–34) spray for 3 months increased lumbar bone mineral density (L-BMD) in a dose-dependent manner, and the PTH1000 group showed a 2.4% increase in L-BMD from baseline. Only the 1,000-μg dose produced consistent and statistically significant changes in markers of bone turnover; after 3 months, median serum type I procollagen N-propeptide (PINP) and osteocalcin increased 14.8% and 19.4% from baseline, while urinary type I collagen N-telopeptide (NTX) decreased 16.4%. Seven subjects developed transient hypercalcemia at 3 h after nasal hPTH(1–34) spray, but none of the subjects developed sustained hypercalcemia.

Conclusion

These observations demonstrate that nasal hPTH(1–34) spray is safe and well tolerated and can rapidly increase L-BMD. The results warrant further studies to examine its long-term efficacy on bone mass and fractures.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441

    Article  PubMed  CAS  Google Scholar 

  2. Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, Lindsay R (2003) Efficacy and safety of human parathyroid hormone-(1–84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 88:5212–5220

    Article  PubMed  CAS  Google Scholar 

  3. Miki T, Nakatsuka K, Naka H, Masaki H, Imanishi Y, Ito M, Inaba M, Morii H, Nishizawa Y (2004) Effect and safety of intermittent weekly administration of human parathyroid hormone 1–34 in patients with primary osteoporosis evaluated by histomorphometry and microstructural analysis of iliac trabecular bone before and after 1 year of treatment. J Bone Mineral Metab 22:569–576

    Article  CAS  Google Scholar 

  4. Orimo H, Sugioka Y, Fukunaga M et al (1998) Diagnostic criteria of primary osteoporosis. J Bone Miner Metab 16:139–150

    Article  Google Scholar 

  5. Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-Hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331–337

    Article  PubMed  CAS  Google Scholar 

  6. Kohno T, Murasugi N, Sakurai H, Watabe K, Nakamuta H, Koida M, Sugie Y, Nomura M, Yanagawa A (1998) Development of a highly sensitive and specific two-site enzyme immunoassay for parathyroid hormone (1–34): application to pharmacokinetic study on intranasal parathyroid hormone (1–34) in human. J Clin Lab Anal 12:268–275

    Article  PubMed  CAS  Google Scholar 

  7. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) study group. Osteoporos Int 11:83–91

    Article  PubMed  CAS  Google Scholar 

  8. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant K, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group. Lancet 348:1535–1541

    Article  PubMed  CAS  Google Scholar 

  9. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637–645

    Article  PubMed  CAS  Google Scholar 

  10. Marcus R, Wang O, Satterwhite J, Mitlak B (2003) The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 18:18–23

    Article  PubMed  CAS  Google Scholar 

  11. Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB (2005) Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20:962–970

    Article  PubMed  CAS  Google Scholar 

  12. Ettinger B, San Martin J, Crans, Gerald, Crans G, Pavo I (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745–751

    Article  PubMed  CAS  Google Scholar 

  13. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207–1215

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The following investigators participated in the trial: Shiro Murakoshi, Sapporo Orthopaedic and Circulatory Hospital; Kimiyoshi Tsuga, Sapporo Maruyama Orthopaedic Hospital; Tomoko Hasunuma, The Kitasato Institute Bioiatric Center; Hikaru Ishii, Shin-nihonbashi Ishii Clinic; Masanari Omata, Oimachi Orthopaedic Clinic; Noriyuki Fujita, Komonji Hospital; Keizo Ohmori, Fukuoka Wajiro Hospital; and Hiroo Yamane, Toyooka Dai-Ichi Hospital. The authors thank Dr. Paul Langman for his assistance with English usage. This work was funded by Chugai Pharmaceutical Co., Ltd.

Author information

Authors and Affiliations

  1. Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Health Biosciences, Tokushima, 770-8503, Japan

    T. Matsumoto

  2. Research Institute and Practice for Involutional Diseases, Nagano, Japan

    M. Shiraki

  3. Tottori University, Tottori, Japan

    H. Hagino

  4. The Cardiovascular Institute, Tokyo, Japan

    H. Iinuma

  5. University of Occupational and Environmental Health, Fukuoka, Japan

    T. Nakamura

Authors
  1. T. Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Shiraki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Hagino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Iinuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Matsumoto.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Matsumoto, T., Shiraki, M., Hagino, H. et al. Daily nasal spray of hPTH(1–34) for 3 months increases bone mass in osteoporotic subjects: a pilot study. Osteoporos Int 17, 1532–1538 (2006). https://doi.org/10.1007/s00198-006-0159-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-006-0159-1

Keywords

Search

Navigation